Detalhe da pesquisa
1.
Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis.
Diabetes Obes Metab
; 26(1): 191-200, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37814928
2.
Cardiorenal Outcomes with Finerenone in Asian Patients with Chronic Kidney Disease and Type 2 Diabetes: A FIDELIO-DKD post hoc Analysis.
Am J Nephrol
; 54(9-10): 370-378, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37708857
3.
Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint study (CONFIDENCE).
Nephrol Dial Transplant
; 38(4): 894-903, 2023 03 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-35700142
4.
Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline.
Diabetes Obes Metab
; 25(6): 1512-1522, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-36722675
5.
Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.
J Am Soc Nephrol
; 33(1): 225-237, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34732509
6.
Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
Nephrol Dial Transplant
; 37(7): 1261-1269, 2022 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34850173
7.
Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial.
Diabetes Obes Metab
; 24(1): 125-134, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34580995
8.
Outcomes With Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Baseline Insulin Resistance.
Diabetes Care
; 47(3): 362-370, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38151465
9.
Risk of chronic kidney disease in patients with acute kidney injury following a major surgery: a US claims database analysis.
Clin Kidney J
; 16(12): 2461-2471, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-38046015
10.
Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial.
Diabetes Res Clin Pract
; 204: 110908, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37805000
11.
Finerenone in Hispanic Patients With CKD and Type 2 Diabetes: A Post Hoc FIDELITY Analysis.
Kidney Med
; 5(10): 100704, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37745646
12.
Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.
Eur J Heart Fail
; 24(6): 996-1005, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35239204
13.
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.
Diabetes Care
; 45(4): 888-897, 2022 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35061867
14.
Finerenone in Predominantly Advanced CKD and Type 2 Diabetes With or Without Sodium-Glucose Cotransporter-2 Inhibitor Therapy.
Kidney Int Rep
; 7(1): 36-45, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-35005312
15.
Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888-897.
Diabetes Care
; 46(9): 1721, 2023 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37310695